Plasma IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue syndrome

Scandinavian Journal of Medicine and Science in Sports

Volumn 20, Issue 2, 2010, Pages 282-290

  Robinson, M ^a   Gray, S R ^a   Watson, M S ^a   Kennedy, G ^b   Hill, A ^b   Belch, J J F ^b   Nimmo, M A ^a,b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Oxidative stress

Indexed keywords

GLYCOPROTEIN GP 130; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPROSTANE DERIVATIVE; LACTIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC FATIGUE SYNDROME; EXERCISE; EXERCISE TEST; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OXYGEN CONSUMPTION; PHYSIOLOGY;

ADULT; AGED; CASE-CONTROL STUDIES; CYTOKINE RECEPTOR GP130; EXERCISE TEST; F2-ISOPROSTANES; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; INTERLEUKIN-6; LACTATES; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PHYSICAL EXERTION; RECEPTORS, INTERLEUKIN-6;

EID: 77951654973     PISSN: 09057188     EISSN: 16000838     Source Type: Journal    
DOI: 10.1111/j.1600-0838.2009.00895.x     Document Type: Article

References (43)

1. Beaver WL, Wasserman K, Whipp BJ. Improved detection of lactate threshold during exercise using a log-log transformation. J Appl Physiol 1985, 59:1936-1940.
2. Bruunsgaard H, Ladelund S, Pedersen AN, Jorgensen T, Pedersen BK. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 2003, 132:24-31.
3. Chow D, He X, Snow AL, Rose-John S, Garcia KC. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 2001, 291:2150-2155.
4. De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Exercise capacity in chronic fatigue syndrome. Arch Intern Med 2000, 160:3270-3277.
5. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994, 93:2114-2119.
6. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996, 16:695-700.
7. Durnin JV, Womersley J. Total body fat, calculated from body density, and its relationship to skinfold thickness in 571 people aged 12-72 years. Proc Nutr Soc 1973, 32:45A.
8. Evengard B, Schacterle RS, Komaroff AL. Chronic fatigue syndrome: new insights and old ignorance. J Intern Med 1999, 246:455-469.
9. Finaud J, Lac G, Filaire E. Oxidative stress: relationship with exercise and training. Sports Med 2006, 36:327-358.
10. Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vessby B, Kallner A, Sjoberg LB, Pedersen BK. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 2004, 558:633-645.
11. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994, 121:953-959. International Chronic Fatigue Syndrome Study Group.
12. Fulcher KY, White PD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 2000, 69:302-307.
13. Gray SR, Robinson M, Nimmo MA. Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men. Cell Stress Chaperones 2008, 13:247-251.
14. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157.
15. Hughson RL, Weisiger KH, Swanson GD. Blood lactate concentration increases as a continuous function in progressive exercise. J Appl Physiol 1987, 62:1975-1981.
16. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005, 257:299-310.
17. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005, 175:3463-3468.
18. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005, 25:241-253.
19. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 2005, 39:584-589.
20. Kosmidou I, Vassilakopoulos T, Xagorari A, Zakynthinos S, Papapetropoulos A, Roussos C. Production of interleukin-6 by skeletal myotubes. Role of reactive oxygen species. Am J Respir Cell Mol Biol 2002, 26:587-593.
21. Meyer T, Gabriel HH, Kindermann W. Is determination of exercise intensities as percentages of VO2max or HRmax adequate? Med Sci Sports Exerc 1999, 31:1342-1345.
22. Mori TA, Croft KD, Puddey IB, Beilin LJ. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal Biochem 1999, 268:117-125.
23. Morrow JD. The isoprostanes - unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Des 2006, 12:895-902.
24. Nijs J, Meeus M, McGregor NR, Meeusen R, de Schutter G, van Hoof E, de Meirleir K. Chronic fatigue syndrome: exercise performance related to immune dysfunction. Med Sci Sports Exerc 2005, 37:1647-1654.
25. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95:56-61.
26. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. J Physiol 1998, 513:889-894.
27. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999, 515:287-291.
28. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007, 29:185-209.
29. Patterson S, Reid S, Gray S, Nimmo M. The response of plasma interleukin-6 and its soluble receptors to exercise in the cold in humans. J Sports Sci 2008, 26:927-933.
30. Paul L, Wood L, Behan WMH, Maclaren WM. Demonstration of delayed recovery from fatiguing exercise in chronic fatigue syndrome. Eur J Neurol 1999, 6:63-69.
31. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol 2007, 103((3)):1093-1098.
32. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006, 57((Suppl. 10)):43-51.
33. Robson-Ansley PJ, Milander L, Collins M, Noakes TD. Acute interleukin-6 infusion impairs athletic performance in healthy, trained male runners. Can J Appl Physiol 2004, 29:411-418.
34. Saris WH, Blair SN, van Baak MA, Eaton SB, Davies PS, Di Pietro L, Fogelholm M, Rissanen A, Schoeller D, Swinburn B, Tremblay A, Westerterp KR, Wyatt H. How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st stock conference and consensus statement. Obes Rev 2003, 4:101-114.
35. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006, 63:321-329.
36. Sorensen B, Streib JE, Strand M, Make B, Giclas PC, Fleshner M, Jones JF. Complement activation in a model of chronic fatigue syndrome. J Allergy Clin Immunol 2003, 112:397-403.
37. Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998, 83:1573-1579.
38. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003, 285:E433-E437.
39. Steinberg JG, Ba A, Bregeon F, Delliaux S, Jammes Y. Cytokine and oxidative responses to maximal cycling exercise in sedentary subjects. Med Sci Sports Exerc 2007, 39:964-968.
40. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
41. Vassilakopoulos T, Karatza MH, Katsaounou P, Kollintza A, Zakynthinos S, Roussos C. Antioxidants attenuate the plasma cytokine response to exercise in humans. J Appl Physiol 2003, 94:1025-1032.
42. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002, 8:75-79.
43. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol Online 1949, 109:1-9.